Supplementary Figure 2 from Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status

Authors :: Annette K. Larsen
Aimery de Gramont
Thierry André
Christophe Tournigand
Benoist Chibaudel
Ariel Savina
Alexandre E. Escargueil
Michèle Sabbah
Nathalie Ferrand
Anaïs Bouygues
Paul Mésange
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: The expression of total VEGFR1 and VEGFR2 was determined by ELISA analysis of tumor extracts (3 tumors per treatment).

Full Text Access

Tools